Furuya Hideki, Shimizu Yoshiko, Tamashiro Paulette M, Iino Kayoko, Bielawski Jacek, Chan Owen T M, Pagano Ian, Kawamori Toshihiko
Cancer Biology Program, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA.
Clinical and Translational Research Program, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA.
J Transl Med. 2017 Jun 6;15(1):120. doi: 10.1186/s12967-017-1220-x.
Accumulating evidence suggests that sphingosine kinase 1 (SphK1)/sphingosine 1-phosphate pathway plays a pivotal role in colon carcinogenesis.
To further support the evidence, we investigated the effects of SphK1 using three separate animal models: SphK1 knockout mice, SphK1 overexpressing transgenic mice, and SphK1 overexpression in human colon cancer xenografts. Using azoxymethane (AOM, colon carcinogen), we analyzed colon tumor development in SphK1 KO and SphK1 overexpression in intestinal epithelial cells regulated by a tet-on system. Then, we analyzed subcutaneous tumor growth using xenografts of HT-29 human colon cancer cell. Finally, immunohistochemical analyses for SphK1 and COX-2 were performed on human colon cancer tissue microarray.
SphK1 KO mice, compared to wild-type mice, demonstrated a significant inhibition in colon cancer development induced by AOM (58.6% vs. 96.4%, respectively, P < 0.005). Tumor multiplicity (1.00 vs. 1.64 per colon, respectively, P < 0.05) and tumor volume (14.82 mm vs. 29.10 mm, P < 0.05) were both significantly reduced in SphK1 KO mice compared to wild-type mice. Next, SphK1 overexpression in HT-29 enhanced tumor growth as compared to GFP control in nude mice (229.5 mm vs. 90.9 mm, respectively, P < 0.05). Furthermore, overexpression of SphK1 in intestinal epithelial cells significantly enhances AOM-induced colon tumor formation (P < 0.05). Lastly, SphK1 and COX-2 intensity tended to reduce overall survival of late stage colon cancer patients.
SphK1 expression regulates the early stage of colon carcinogenesis and tumor growth, thus inhibition of SphK1 may be an effective strategy for colon cancer chemoprevention.
越来越多的证据表明,鞘氨醇激酶1(SphK1)/1-磷酸鞘氨醇途径在结肠癌发生过程中起关键作用。
为进一步证实这一证据,我们使用三种不同的动物模型研究了SphK1的作用:SphK1基因敲除小鼠、SphK1过表达转基因小鼠以及人结肠癌异种移植模型中SphK1的过表达。使用氧化偶氮甲烷(AOM,一种结肠癌致癌物),我们分析了SphK1基因敲除小鼠和通过四环素诱导系统在肠上皮细胞中过表达SphK1的小鼠的结肠肿瘤发展情况。然后,我们使用HT-29人结肠癌细胞异种移植模型分析了皮下肿瘤生长情况。最后,对人结肠癌组织芯片进行了SphK1和COX-2的免疫组化分析。
与野生型小鼠相比,SphK1基因敲除小鼠的AOM诱导的结肠癌发展受到显著抑制(分别为58.6%和96.4%,P < 0.005)。与野生型小鼠相比,SphK1基因敲除小鼠的肿瘤多发性(分别为每只结肠1.00个和1.64个,P < 0.05)和肿瘤体积(14.82 mm和29.10 mm,P < 0.05)均显著降低。其次,与裸鼠中的绿色荧光蛋白(GFP)对照相比,HT-29细胞中SphK1的过表达增强了肿瘤生长(分别为229.5 mm和90.9 mm,P < 0.05)。此外,肠上皮细胞中SphK1的过表达显著增强了AOM诱导的结肠肿瘤形成(P < 0.05)。最后,SphK1和COX-2的表达强度倾向于降低晚期结肠癌患者的总体生存率。
SphK1的表达调节结肠癌发生的早期阶段和肿瘤生长,因此抑制SphK1可能是结肠癌化学预防的有效策略。